29 results about "Digoxin" patented technology

The invention relates to the technical field of biological products, and discloses a mesenchymal stem cell hair growth liquid and a preparation method thereof, and the mesenchymal stem cell hair growth liquid comprises the following components: hair follicle mesenchymal stem cells; a hair follicle mesenchymal stem cell exosome; growth factors: a vascular endothelial growth factor (VEGF), a fibroblast growth factor (FGFs), a keratinocyte growth factor (KGF-7) and interleukin-10 (IL-10); vitamins: vitamin E, vitamin B5, vitamin B2, vitamin B6, vitamin C and biotin; the plant extracts comprise a cacumen biotae extract, a polygonum multiflorum extract, a ginseng extract, a peppermint extract, a purslane extract and a rhodiola rosea extract; other active ingredients: tripeptide and digoxin; the auxiliary material is a hyaluronic acid-collagen peptide graft copolymer; and the balance of a phosphate buffer solution.

The application provides an anti-digoxin antibody or antigen binding fragment thereof and application thereof, and relates to the technical field of antibodies. The anti-digoxin antibody or antigen binding fragment thereof comprises a heavy chain variable region and a light chain variable region; the heavy chain variable region comprises VHCDR1 of the 17th-24th amino acid residues at the N terminus of the amino acid sequence shown in SEQ ID NO. 1, VHCDR2 of the 42nd-49th amino acid residues, and VHCDR3 of the 88th-98th amino acid residues; and the light chain variable region comprises VLCDR1 of the 27th-37th amino acid residues at the N terminus of the amino acid sequence shown in SEQ ID NO. 2, VLCDR2 of the 55th-57th amino acid residues, and VLCDR3 of the 94th-102th amino acid residues. The antibody or antigen binding fragment thereof can be used for immunological detection, and has been verified to have good specific binding capacity.

The application provides a quantum dot microsphere fluorescent immunochromatography test paper for combined detection of ASFV antibodies and nucleic acids and an application thereof, and belongs to the technical field of veterinary biological diagnosis products. The quantum dot microsphere fluorescent immunochromatography test paper for combined detection of ASFV antibodies and nucleic acids comprises a base plate, on the base plate, a sample pad, a combination pad, a nitrocellulose membrane and a water absorption pad are sequentially connected in a head-to-tail mode, from the combination pad to the water absorption pad, the nitrocellulose membrane is sequentially provided with an antibody detection line, a nucleic acid detection line and a quality control line, the antibody detection line is coated with a goat anti-pig IgG-Fc antibody, the nucleic acid detection line is coated with streptavidin, and the quality control line is coated with a rabbit anti-sheep IgG antibody; the combination pad is coated with a quantum dot microsphere labeled recombinant protein P22 and a quantum dot microsphere labeled sheep anti-digoxin antibody. The test paper can rapidly, highly specifically and highly sensitively detect ASFV antibodies and nucleic acids.

The invention discloses a digoxin drug concentration detection method, which comprises: S1, determining a to-be-detected drug, and carrying out working curve preparation on a detection object, the to-be-detected drug being digoxin; s2, taking out the to-be-detected sample, the calibration product, the quality control product and the internal standard extraction liquid, placing at room temperature, and uniformly mixing; s3, respectively taking a to-be-detected sample, a calibration product, a quality control product and a blank sample, putting into an EP tube, adding the internal standard intermediate solution, adding methanol, uniformly mixing by vortex, and centrifuging; s4, putting the supernate into a 96-well plate, adding ultrapure water, and putting the 96-well plate on a microwell plate oscillator for shaking; and S5, centrifuging in a multi-tube rack automatic balancing centrifuge, detecting and verifying by using liquid chromatogram-tandem mass spectrum, and collecting a mass spectrum signal. According to the present invention, the high performance liquid chromatography separation and the mass spectrometry are combined, such that the complex background interference in the blood sample is overcome, the cost performance is improved, and the high sensitivity, the high accuracy and the convenient detection can be achieved for the digoxin sample with the low in-vivo concentration.

This application relates to the technical field of biomarkers, and particularly to a preparation method and application of an RNA vector-related translocation complex; the translocation complex includes an RNA vector, and the RNA vector includes an RNA vector core sequence, a biotin-labeled primer, and a digoxigenin-labeled primer. The forward sequence of the RNA vector core sequence is shown in SEQ ID NO.1, and the reverse sequence of the RNA vector core sequence is shown in SEQ ID NO.2; through the RNA vector including the RNA vector core sequence, the biotin-labeled primer, and the digoxigenin-labeled primer, one end of the RNA vector is connected to streptomycin-coated magnetic beads through the biotin-labeled primer, and the other end is connected to the digoxigenin-treated glass surface, with firm binding. The RNA vector core region can form a translocation complex with the Holo-RdRp polymerase and the nsp13 helicase, and the single-molecule magnetic tweezer technology can effectively reflect the kinetic characteristics of the nsp13 reaction in real time.

The present invention relates to the field of pharmaceutical technology, and specifically to the application of a macrolide derivative in the preparation of a drug for treating heart failure. The present invention provides a new use of a macrolide derivative. Experimental results show that this macrolide derivative significantly improves the cardiac function of heart failure mice, increases the ejection fraction (EF%), fractional shortening (FS%), and cardiac output per minute (CO), without changing the heart rate (HR), is equivalent to the positive drug digoxin, and is superior to enalapril; at the same time, it has the effects of reducing the heart weight ratio, improving myocardial hypertrophy and fibrosis, and has good clinical prospects and social benefits.

The invention provides a dilated cardiomyopathy child death risk prediction method, system and device, and relates to the technical field of medical prediction models.The method comprises the steps that clinical data of a target dilated cardiomyopathy child patient are obtained and input into a pre-constructed nomogram prediction model, and death risk prediction results of the target dilated cardiomyopathy child patient at multiple time points in the future are output; the nomogram prediction model is constructed through independent prediction factors, the amino-terminal brain natriuretic peptide precursor level, the gender and the digoxin use condition which are determined through single-factor and multi-factor Cox regression analysis. According to the method, the nomogram prediction model is constructed by integrating the key clinical variables, accurate prediction and individualized treatment guidance of the dilated cardiomyopathy death risk of children are achieved, and the accuracy of clinical decision and the prognosis management effect are effectively improved.

This application relates to a digoxin detection kit. Specifically, the 6-glucose phosphate dehydrogenase mutant of this application comprises one or a combination of the following mutations compared to wild-type 6-glucose phosphate dehydrogenase: D306C, D375C, and G426C. The detection kit prepared using the 6-glucose phosphate dehydrogenase mutant of this application has strong specificity, high sensitivity, convenient operation, short detection time, and accurate quantitative determination, making it suitable for high-throughput detection.

At least one pharmaceutical composition for use in a method of prophylaxis or treatment of COVID wherein the at least one pharmaceutical composition comprises donepezil, rivastigmine or galantamine or one of donepezil, rivastigmine or galantamine combined with one of: Artemether and Lumefantrine; Atazanavir Sulfate; Efavirenz; Fosamprenavir Calcium; Saquinavir; Remdesivir (GS-5734); Digoxin; Memantine; Rivastigmine; Galantamine; Valsartan; Teriflunomide and wherein the method of prophylaxis or treatment of COVID or COVID-19 comprises: providing a subject in need of said prophylaxis or treatment; providing the at least one pharmaceutical composition as defined supra; wherein said components are provided together or separately; wherein said components are administered together or separately; and wherein said components are provided in a pharmaceutically acceptable diluent, adjuvant and / or excipient; and administering a pharmaceutically effective amount of said at least one pharmaceutical composition to said subject; and wherein, in the method, said subject is provided prophylaxis or treatment of COVID and COVID relates to a human coronavirus, mouse hepatitis virus (MHV), or recombinant mouse-adapted SARS-CoV (SARS-CoV MAI 5).

The application discloses a digoxin nanobody and a preparation method and application thereof. The amino acid and nucleotide sequences of the digoxin nanobody are shown in SEQ ID NO. 8-9. The antibody has good affinity to a target antigen, and the dissociation constant Kd value is about 73.1 nM, and can be used for digoxin content determination, nucleic acid probe detection and in-vivo digoxin neutralization and detoxification. The antibody has the advantages of small volume, high stability, low cost, low immunogenicity and the like, and has a good application prospect.

The present invention relates to a humanized antibody having excellent binding affinity for digoxigenin and its uses. When using an antibody or an antigen-binding fragment thereof that specifically recognizes digoxigenin according to an embodiment of the present invention, it can be expected to regulate the concentration of a drug in vivo as needed or increase the half-life of the drug in a living body by means of a complex (DOligobody) containing the same.

The invention relates to application of an activating agent in promotion of uranium element discharge. Specifically, the activating agent is prepared from rifampicin, erythromycin, progesterone, aldosterone, bilirubin, cholate vinblastine, doxomicin, adriamycin, paclitaxel, bosentan, ambrisentan, digoxin, verapamil, tonavir, amprenavir, indinavir, hypericum perforatum juice, curcumin, atorvastatin beclomethasone, budesonide, divaricasone carbamazepine and caffeine. And phenytoin. The use dosage of the activating agent is 10 to 60 mg / kg. According to the method, the accumulation amount of uranium in important organs such as bones and kidneys can be remarkably reduced, so that the potential toxic influence on the key organs is reduced.

The invention relates to a digoxin immunodetection reagent as well as a preparation method and a detection method thereof, in particular to a digoxin chemiluminescence immunodetection reagent as well as a preparation method and a detection method thereof, and the digoxin chemiluminescence immunodetection reagent comprises an anti-digoxin specific antibody and an indicating reagent for detecting an anti-digoxin specific antibody-digoxin conjugate, the anti-digoxin specific antibody is obtained by immunizing animals with digoxin immunogen. The digoxin immunogen has the beneficial effects that the digoxin immunogen has strong specificity and high immunogenicity, and the prepared anti-digoxin specific antibody has strong specificity and high titer; the chemiluminescence immunoassay reagent containing the anti-digoxin specific antibody can conveniently, quickly and accurately determine the content of digoxin in a sample, can simultaneously determine a plurality of samples on a full-automatic chemiluminescence immunoassay analyzer, realizes high-flux quick determination of digoxin, and is high in accuracy, strong in specificity and high in sensitivity. And the accuracy and the detection efficiency are greatly improved.

The invention belongs to the technical field of biology, and particularly discloses an anti-digoxin monoclonal antibody and application thereof. A conjugate DIG-BSA of hapten in-situ goxin and BSA is used as an artificial complete antigen to immunize a BALB / c mouse, a hybridoma cell strain DIG-14B4 capable of stably secreting an anti-DIG monoclonal antibody is screened out by utilizing sandwich ELISA, and then the anti-DIG monoclonal antibody with high affinity and high specificity is prepared by adopting an in-vivo ascites inducing method. The anti-DIG monoclonal antibody can be used for immunochromatography detection and can accurately, sensitively, quickly and specifically detect protein or nucleic acid molecules labeled by a DIG probe, so that qualitative and semi-quantitative detection of target protein or nucleic acid molecules is realized.

The invention belongs to the technical field of molecular biology, and discloses a preparation method of a fluorescence in situ hybridization kit based on a hybridization chain reaction (HCR), the core components of the kit comprise a hybridization probe, an amplification probe, a washing liquid, a confining liquid, protease K, HRP-mouse anti-digoxin, and a TSA developing liquid 520 nm. According to the FISH detection system combined with the HCR signal amplification technology, when a hybridization probe and an amplification probe are simultaneously combined to a position adjacent to a target sequence, a small section of sequence at the top end can trigger a branched HCR reaction to form a macromolecular nucleic acid aggregate. Signal amplification of HCR is achieved through cascade hybridization reaction, detection sensitivity and specificity can be remarkably improved, and meanwhile the problem of background noise caused by a traditional enzymatic method is avoided. The kit disclosed by the invention is wide in sample application range, and can be used for positioning analysis of target RNA of samples such as paraformaldehyde or formalin-fixed animal and plant tissues, paraffin or frozen sections, cells and the like, and high-sensitivity detection of the single cell level of non-coding RNA.

This invention belongs to the pharmaceutical field, specifically relating to the application of the combination of digetuxine and Lactobacillus reuteri in the preparation of an anti-amputation carcinoma drug. Through in vitro MTT assays of antitumor activity, this invention found that the combination of the cardiac glycoside drug digetuxine and the probiotic Lactobacillus reuteri can inhibit the proliferation of ampullary cancer cells and has a good inhibitory effect on ampullary carcinoma xenograft models. Furthermore, this combination alleviates the intestinal toxicity of digetuxine, and its therapeutic effect is superior to that of the commonly used clinical drug 5-fluorouracil, showing promising application prospects.

The invention discloses an application of Digoxin in preparation of a medicine for treating and / or preventing tumors. It is found for the first time that Digoxin can enhance the esophageal cancer radiotherapy sensitivity. Digoxin is a medicine which is approved by FDA, small in toxic and side effects and moderate in price, can be prepared into capsules for oral administration, and is used for radiotherapy sensitization of esophageal cancer and inhibition of growth of esophageal cancer.

The application provides a digoxin microtablet and a preparation method thereof. The digoxin microtablet prepared by the application contains 5-100 micrograms of digoxin per tablet, which can meet the dosage requirements of patients of different ages, realize precise dosage administration, and reduce the risk of drug overdose in clinical application. The digoxin microtablet provided by the application can solve the problem that infants and children have difficulty in swallowing the medicine, thereby improving the medication compliance of infants and children. Compared with conventional tablets, the microtablet has a smaller volume. The digoxin microtablet provided by the application is prepared by optimizing the prescription and process, preparing a digoxin compound by a spray drying and hot melt extrusion technology, obtaining a solid dispersion, and having better content uniformity and dissolution rate, and significantly improving the bioavailability.

The invention relates to the field of a preparation method and application of an adriamycin liposome nano-drug, in particular to a preparation method and application of an ionizable adriamycin liposome nano-drug taking digoxin as a fifth component. The protonation effect (piperazine with a tertiary amine structure is protonated to form cations under an acidic condition) of an ionizable lipid delivery carrier under the action of an acidic microenvironment of tumor tissues is utilized to repel protonated DOX, so that the DOX is quickly and efficiently released, and the toxic and side effects of DOX-coated D-LNP are reduced; the medicine DIG with the cardiovascular protection effect is used for reducing the DOX-mediated cardiotoxicity; and meanwhile, the anti-tumor effect of the DOX-coated D-LNP is improved by utilizing the anti-tumor effect of the DIG.

This invention relates to the field of diclofenac preparation technology and discloses a method for preparing high-purity diclofenac, comprising the following steps: synthesis of BOC-D-phenylalanine-D-phenylalanine-D-leucine-N'-BOC-D-lysine; synthesis of BOC-D-phenylalanine-D-phenylalanine-D-leucine-N'-BOC-D-lysine-4-(Trt-amino)piperidine-4-carboxylic acid ethyl ester; synthesis of D-phenylalanine-D-phenylalanine-D-leucine-D-lysine-4-aminopiperidine-4-carboxylic acid ethyl ester; and synthesis of diclofenac. The key intermediates in the synthesis process of this invention can be obtained by precipitation or recrystallization, without the need for purification using chromatography columns or HPLC, offering advantages such as convenient operation and low cost, and ultimately producing high-purity diclofenac.

1. The name of the design product: packaging box (digoxin injection). 2. The use of the design product: the design product is used for packaging medicines. 3. The design points of the design product: the pattern of the product. 4. The picture or photo that best indicates the design points: front view.

The invention provides a mycoplasma pneumoniae / chlamydia combined detection method, which efficiently enriches target genes through cascade reaction of RPA (recombinase polymerase amplification) pre-amplification (37 DEG C + / -1 DEG C, 5 minutes) and LAMP (loop-mediated isothermal amplification) targeted amplification (40 DEG C + / -2 DEG C, 15 minutes). A dUTP / UDG anti-pollution system and a closed tube operation process are adopted, an amplification product is directly mixed with a double-labeled colloidal gold probe, and double pathogens are synchronously detected through an immunochromatography test strip. The test strip is provided with two independent detection lines, FAM and digoxin reporter molecules are captured respectively, detection is completed within 25 minutes, sensitivity is high, cross contamination is avoided, and the test strip is suitable for rapid diagnosis of basic respiratory pathogens.

This invention relates to the field of biology, and particularly to a ligand-coupled microsphere for measuring inverse-locking levels, its preparation method, and a method for measuring inverse-locking levels. The ligand-coupled microsphere comprises a ligand coupled with a first label, a DNA fragment, and a polystyrene microsphere. A second label is coupled to one end of the DNA fragment, and the second label specifically binds to the first label. Digoxigenin is coupled to the other end of the DNA fragment. An anti-digoxigenin antibody is coupled to the surface of the polystyrene microsphere, and the polystyrene microsphere is linked to the DNA fragment via the anti-digoxigenin antibody and digoxigenin. The measurement method of this invention can measure different receptor-ligand interactions and enables its application in commercial instruments, forming a more universal inverse-locking measurement method. This allows inverse-locking measurements to be applied in more situations, providing theoretical support for the engineering modification of various receptors such as TCR, and providing data support for clinical applications.

The invention belongs to the field of nucleic acid detection, and discloses a method for detecting oligonucleotide drugs based on an MSD (Meso Scale Discovery) platform and application of the method. According to the method, high-sensitivity quantitative detection is realized by designing a specific probe system: a capture probe and a detection probe are synergistically hybridized with target oligonucleotide to form a compound, the compound is fixed on a streptavidin-coated MSD plate, an anti-digoxin-SULFO-TAG antibody is combined, and a signal is detected by an electrochemical luminescence method. The innovation points are as follows: LNA modification enhances the stability and specificity of the probe, and the use amount of the probe is reduced by 50%; the process of a non-enzyme reaction system is simplified to 4 hours; sample treatment is optimized (RNALater is added to inhibit RNA enzyme degradation), and the method is suitable for complex matrixes such as serum and tissue homogenate. The sensitivity reaches 0.4 pM, the linear range spans five orders of magnitude, high specificity and high flux are achieved, and efficient and reliable technical support is provided for research and development of oligonucleotide drugs, pharmacokinetic research and clinical tests.

The present invention discloses a DNA probe for detecting nucleic acids of pathogens of urogenital tract infections and its application. The pathogens of urogenital tract infections include Chlamydia trachomatis, Neisseria gonorrhoeae, and Mycoplasma genitalium. The DNA probe comprises probe H1 and probe H2. The DNA probe is mixed with a target sequence to undergo a catalytic hairpin self-assembly reaction. The 5' end of probe H1 is modified with digoxigenin, and the 5' end of probe H2 is modified with biotin. The present invention utilizes the DNA probe and target sequence to catalyze the hairpin self-assembly reaction, combined with an immunochromatographic test strip, to rapidly, highly sensitively, and specifically detect Chlamydia trachomatis, Neisseria gonorrhoeae, and Mycoplasma genitalium in an isothermal, enzyme-free amplification environment.

The invention relates to an oral pharmaceutical composition of diillain, which comprises diillain, a delivery agent, an auxiliary agent and an optional pharmaceutically acceptable inactive component, and can have good bioavailability and reduced variability of drug effectiveness.

The invention belongs to the field of quantitative cell incubation liquid drug concentration analysis, and particularly discloses a method for simultaneously detecting atenolol and digoxin in a cell incubation liquid. According to the method, the concentrations of atenolol and digoxin in the Hanke equilibrium salt buffer solution co-incubated with the cells can be accurately quantified at the same time through specific sample treatment and liquid chromatography and mass spectrometry conditions, the sensitivity is high, the detection limit is low, the normal excretion and transmembrane transport functions of Caco-2 cells in the research process are investigated, and the method has application and popularization value.

The present invention relates to humanized antibodies having good binding ability to digoxigenin and uses thereof. When an antibody or antigen-binding fragment thereof specifically recognizing digoxigenin according to one aspect of the present invention is used, the concentration of the drug in the body is adjusted as needed through a complex (DOligobody) containing the same, or the concentration of the drug in vivo It is expected that the half-life can be increased.

The present invention relates to a novel proteasome inhibitor comprising a digoxigenin-derived lactone ring-based compound as an active ingredient, and can simultaneously exhibit high 20S proteasome inhibitory activity and low normal cell toxicity. The compound has excellent cancer cell selectivity, has pharmacological properties with improved anticancer effects and therapeutic indices, and can be useful for various carcinomas such as multiple myeloma, breast cancer, and hepatocellular carcinoma.